Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.

Melosky B, Bradbury P, Tu D, Florescu M, Reiman A, Nicholas G, Basappa N, Rothenstein J, Goffin JR, Laurie SA, Wheatley-Price P, Leighl N, Goss G, Reaume MN, Butts C, Murray N, Card C, Ko J, Blais N, Gray S, Lui H, Brown-Walker P, Kaurah P, Prentice LM, Seymour L.

Lung Cancer. 2019 Jul;133:48-55. doi: 10.1016/j.lungcan.2019.04.027. Epub 2019 May 1.

PMID:
31200828
2.

Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.

Gotfrit J, Jonker C, Zhang T, Goss G, Nicholas G, Laurie S, Wheatley-Price P.

Cancer Treat Res Commun. 2019;19:100130. doi: 10.1016/j.ctarc.2019.100130. Epub 2019 Mar 23.

PMID:
30927666
3.

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, Laskin J, Leighl N, MacRae R, Nicholas G, Roberge D, Rothenstein J, Stewart DJ, Tsao MS.

Curr Oncol. 2019 Feb;26(1):e81-e93. doi: 10.3747/co.26.4116. Epub 2019 Feb 1.

4.

Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort.

Taghizadeh N, Tremblay A, Cressman S, Peacock S, McWilliams AM, MacEachern P, Johnston MR, Goffin J, Goss G, Nicholas G, Martel S, Laberge F, Bhatia R, Liu G, Schmidt H, Atkar-Khattra S, Tsao MS, Tammemagi MC, Lam SC; Pan-Canadian Early Lung Cancer Study Group.

BMJ Open. 2019 Jan 17;9(1):e024719. doi: 10.1136/bmjopen-2018-024719.

5.

Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.

Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, Foulkes WD, Malkin D, Tabori U, Pearson CE.

J Clin Oncol. 2019 Feb 20;37(6):461-470. doi: 10.1200/JCO.18.00474. Epub 2019 Jan 4.

PMID:
30608896
6.

Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.

Toms SA, Kim CY, Nicholas G, Ram Z.

J Neurooncol. 2019 Jan;141(2):467-473. doi: 10.1007/s11060-018-03057-z. Epub 2018 Dec 1.

7.

A prospective intervention to improve happiness and reduce burnout in oncologists.

Clemons M, Mazzarello S, Pond G, Amir E, Asmis T, Berry S, Brackstone M, Brule S, Goodwin R, Hilton JF, Julião M, Nicholas G, Stewart DJ, Wheatley-Price P, Cholmsky L, Krentel A, Hutton B, Joy AA.

Support Care Cancer. 2019 Apr;27(4):1563-1572. doi: 10.1007/s00520-018-4567-5. Epub 2018 Nov 30.

PMID:
30506102
8.

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.

Goffin JR, Nicholas G, Mates M, Tu D, Chen E, Laurie SA, Juergens R, Robinson A, Goss G, Reaume M, Sun S, Christink K, Maize C, MacFarlan S, Sun X, Ritter H, Seymour L, Bradbury PA.

Invest New Drugs. 2019 Jun;37(3):498-506. doi: 10.1007/s10637-018-0680-z. Epub 2018 Oct 13.

PMID:
30317534
9.

Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?

Al-Baimani K, Jonker H, Zhang T, Goss GD, Laurie SA, Nicholas G, Wheatley-Price P.

Curr Oncol. 2018 Aug;25(4):e291-e297. doi: 10.3747/co.25.3978. Epub 2018 Aug 14.

10.

Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.

Daaboul N, Nicholas G, Laurie SA.

Curr Oncol. 2018 Jun;25(Suppl 1):S77-S85. doi: 10.3747/co.25.3792. Epub 2018 Jun 13. Review.

11.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA.

Lung Cancer. 2018 Jun;120:142-148. doi: 10.1016/j.lungcan.2018.03.005. Epub 2018 Mar 9.

PMID:
29748010
12.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z.

JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.

13.

Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.

Tammemagi MC, Schmidt H, Martel S, McWilliams A, Goffin JR, Johnston MR, Nicholas G, Tremblay A, Bhatia R, Liu G, Soghrati K, Yasufuku K, Hwang DM, Laberge F, Gingras M, Pasian S, Couture C, Mayo JR, Nasute Fauerbach PV, Atkar-Khattra S, Peacock SJ, Cressman S, Ionescu D, English JC, Finley RJ, Yee J, Puksa S, Stewart L, Tsai S, Haider E, Boylan C, Cutz JC, Manos D, Xu Z, Goss GD, Seely JM, Amjadi K, Sekhon HS, Burrowes P, MacEachern P, Urbanski S, Sin DD, Tan WC, Leighl NB, Shepherd FA, Evans WK, Tsao MS, Lam S; PanCan Study Team.

Lancet Oncol. 2017 Nov;18(11):1523-1531. doi: 10.1016/S1470-2045(17)30597-1. Epub 2017 Oct 18.

PMID:
29055736
14.

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.

Leighl NB, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA.

Oncotarget. 2017 Jun 28;8(41):69651-69662. doi: 10.18632/oncotarget.18753. eCollection 2017 Sep 19.

15.

The Impact of Baseline Edmonton Symptom Assessment Scale Scores on Treatment and Survival in Patients With Advanced Non-small-cell Lung Cancer.

McGee SF, Zhang T, Jonker H, Laurie SA, Goss G, Nicholas G, Albaimani K, Wheatley-Price P.

Clin Lung Cancer. 2018 Jan;19(1):e91-e99. doi: 10.1016/j.cllc.2017.05.018. Epub 2017 Jun 8.

PMID:
28666762
16.

Systemic Therapy Outcomes in Adult Patients with Ewing Sarcoma Family of Tumors.

Valdes M, Nicholas G, Verma S, Asmis T.

Case Rep Oncol. 2017 May 23;10(2):462-472. doi: 10.1159/000475806. eCollection 2017 May-Aug.

17.

IGF1 stimulates greater muscle hypertrophy in the absence of myostatin in male mice.

Hennebry A, Oldham J, Shavlakadze T, Grounds MD, Sheard P, Fiorotto ML, Falconer S, Smith HK, Berry C, Jeanplong F, Bracegirdle J, Matthews K, Nicholas G, Senna-Salerno M, Watson T, McMahon CD.

J Endocrinol. 2017 Aug;234(2):187-200. doi: 10.1530/JOE-17-0032. Epub 2017 May 22.

PMID:
28533420
18.

The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency.

Cressman S, Peacock SJ, Tammemägi MC, Evans WK, Leighl NB, Goffin JR, Tremblay A, Liu G, Manos D, MacEachern P, Bhatia R, Puksa S, Nicholas G, McWilliams A, Mayo JR, Yee J, English JC, Pataky R, McPherson E, Atkar-Khattra S, Johnston MR, Schmidt H, Shepherd FA, Soghrati K, Amjadi K, Burrowes P, Couture C, Sekhon HS, Yasufuku K, Goss G, Ionescu DN, Hwang DM, Martel S, Sin DD, Tan WC, Urbanski S, Xu Z, Tsao MS, Lam S.

J Thorac Oncol. 2017 Aug;12(8):1210-1222. doi: 10.1016/j.jtho.2017.04.021. Epub 2017 May 10.

19.

Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.

Ten Haaf K, Tammemägi MC, Bondy SJ, van der Aalst CM, Gu S, McGregor SE, Nicholas G, de Koning HJ, Paszat LF.

PLoS Med. 2017 Feb 7;14(2):e1002225. doi: 10.1371/journal.pmed.1002225. eCollection 2017 Feb.

20.

Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy.

Valdes M, Nicholas G, Goss GD, Wheatley-Price P.

Curr Oncol. 2016 Dec;23(6):386-390. doi: 10.3747/co.23.3191. Epub 2016 Dec 21.

21.

Erratum to: The effect of a locally adapted, secondary stroke risk factor self-management program on medication adherence among veterans with stroke.

Damush TM, Myers L, Anderson JA, Yu Z, Ofner S, Nicholas G, Kimmel B, Schmid AA, Kent T, Williams LS.

Transl Behav Med. 2016 Sep;6(3):469. doi: 10.1007/s13142-016-0412-x. No abstract available.

22.

The effect of a locally adapted, secondary stroke risk factor self-management program on medication adherence among veterans with stroke/TIA.

Damush TM, Myers L, Anderson JA, Yu Z, Ofner S, Nicholas G, Kimmel B, Schmid AA, Kent T, Williams LS.

Transl Behav Med. 2016 Sep;6(3):457-68. doi: 10.1007/s13142-015-0348-6. Erratum in: Transl Behav Med. 2016 Sep;6(3):469.

23.

Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.

Brule SY, Al-Baimani K, Jonker H, Zhang T, Nicholas G, Goss G, Laurie SA, Wheatley-Price P.

Lung Cancer. 2016 Jul;97:15-21. doi: 10.1016/j.lungcan.2016.04.007. Epub 2016 Apr 14. Review.

PMID:
27237022
24.

Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study.

Tremblay A, Taghizadeh N, McWilliams AM, MacEachern P, Stather DR, Soghrati K, Puksa S, Goffin JR, Yasufuku K, Amjadi K, Nicholas G, Martel S, Laberge F, Johnston M, Shepherd FA, Ionescu DN, Urbanski S, Hwang D, Cutz JC, Sekhon HS, Couture C, Xu Z, Sutedja TG, Atkar-Khattra S, Tammemagi MC, Tsao MS, Lam SC; Pan-Canadian Early Lung Cancer Study Group.

Chest. 2016 Nov;150(5):1015-1022. doi: 10.1016/j.chest.2016.04.019. Epub 2016 Apr 30.

PMID:
27142184
25.

Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy.

Saint-Pierre MD, Pease C, Mithoowani H, Zhang T, Nicholas GA, Laurie SA, Wheatley-Price P.

Lung Cancer Int. 2015;2015:590148. doi: 10.1155/2015/590148. Epub 2015 Mar 2.

26.

Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.

Wasserman JK, Nicholas G, Yaworski R, Wasserman AM, Woulfe JM, Jansen GH, Chakraborty S, Nguyen TB.

PLoS One. 2015 Apr 7;10(4):e0123890. doi: 10.1371/journal.pone.0123890. eCollection 2015.

27.

Plasma pro-surfactant protein B and lung function decline in smokers.

Leung JM, Mayo J, Tan W, Tammemagi CM, Liu G, Peacock S, Shepherd FA, Goffin J, Goss G, Nicholas G, Tremblay A, Johnston M, Martel S, Laberge F, Bhatia R, Roberts H, Burrowes P, Manos D, Stewart L, Seely JM, Gingras M, Pasian S, Tsao MS, Lam S, Sin DD; Pan-Canadian Early Lung Cancer Study Group.

Eur Respir J. 2015 Apr;45(4):1037-45. doi: 10.1183/09031936.00184214. Epub 2015 Jan 22. Erratum in: Eur Respir J. 2016 Sep;48(3):962.

28.

Inhibition of glioblastoma malignancy by Lgl1.

Gont A, Hanson JE, Lavictoire SJ, Daneshmand M, Nicholas G, Woulfe J, Kassam A, Da Silva VF, Lorimer IA.

Oncotarget. 2014 Nov 30;5(22):11541-51.

29.

Identification of amino acids associated with skeletal muscle growth in late gestation and at weaning in lambs of well-nourished sheep.

Sales FA, Pacheco D, Blair HT, Kenyon PR, Nicholas G, Senna Salerno M, McCoard SA.

J Anim Sci. 2014 Nov;92(11):5041-52. doi: 10.2527/jas.2014-7689.

PMID:
25349352
30.

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.

Cressman S, Lam S, Tammemagi MC, Evans WK, Leighl NB, Regier DA, Bolbocean C, Shepherd FA, Tsao MS, Manos D, Liu G, Atkar-Khattra S, Cromwell I, Johnston MR, Mayo JR, McWilliams A, Couture C, English JC, Goffin J, Hwang DM, Puksa S, Roberts H, Tremblay A, MacEachern P, Burrowes P, Bhatia R, Finley RJ, Goss GD, Nicholas G, Seely JM, Sekhon HS, Yee J, Amjadi K, Cutz JC, Ionescu DN, Yasufuku K, Martel S, Soghrati K, Sin DD, Tan WC, Urbanski S, Xu Z, Peacock SJ; Pan-Canadian Early Detection of Lung Cancer Study Team.

J Thorac Oncol. 2014 Oct;9(10):1449-58. doi: 10.1097/JTO.0000000000000283.

31.

Discovery of a mammalian splice variant of myostatin that stimulates myogenesis.

Jeanplong F, Falconer SJ, Oldham JM, Thomas M, Gray TS, Hennebry A, Matthews KG, Kemp FC, Patel K, Berry C, Nicholas G, McMahon CD.

PLoS One. 2013 Dec 2;8(12):e81713. doi: 10.1371/journal.pone.0081713. eCollection 2013.

32.

Metaphors and malignancy: making sense of cancer.

Nicholas G.

Curr Oncol. 2013 Dec;20(6):e608-9. doi: 10.3747/co.20.1635. No abstract available.

33.

A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.

Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L, Wang L, Schwock J, Hirsh V, Oza A, Tsao MS, Wright JJ, Leighl NB.

Clin Lung Cancer. 2014 Jan;15(1):52-7. doi: 10.1016/j.cllc.2013.08.001. Epub 2013 Oct 26.

PMID:
24169259
34.

Probability of cancer in pulmonary nodules detected on first screening CT.

McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, Yasufuku K, Martel S, Laberge F, Gingras M, Atkar-Khattra S, Berg CD, Evans K, Finley R, Yee J, English J, Nasute P, Goffin J, Puksa S, Stewart L, Tsai S, Johnston MR, Manos D, Nicholas G, Goss GD, Seely JM, Amjadi K, Tremblay A, Burrowes P, MacEachern P, Bhatia R, Tsao MS, Lam S.

N Engl J Med. 2013 Sep 5;369(10):910-9. doi: 10.1056/NEJMoa1214726.

35.

PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1.

Gont A, Hanson JE, Lavictoire SJ, Parolin DA, Daneshmand M, Restall IJ, Soucie M, Nicholas G, Woulfe J, Kassam A, Da Silva VF, Lorimer IA.

Oncotarget. 2013 Aug;4(8):1266-79.

36.

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.

Chow LQ, Jonker DI, Dy GK, Nicholas G, Fortin C, Patricia D, Adjei AA, Belani CP, Gupta A, Park JS, Zhang S, Sbar EI, Laurie SA.

Cancer Chemother Pharmacol. 2013 May;71(5):1273-85. doi: 10.1007/s00280-013-2126-9. Epub 2013 Mar 7.

PMID:
23468081
37.

Lack of association between allelic status and myostatin content in lambs with the myostatin g+6723G>A allele.

Haynes FE, Greenwood PL, McDonagh MB, McMahon CD, Nicholas GD, Berry CJ, Oddy VH.

J Anim Sci. 2013 Jan;91(1):78-89. doi: 10.2527/jas.2012-5482. Epub 2012 Oct 9.

PMID:
23048142
38.

Assessing numerical dependence in gene expression summaries with the jackknife expression difference.

Stevens JR, Nicholas G.

PLoS One. 2012;7(8):e39570. doi: 10.1371/journal.pone.0039570. Epub 2012 Aug 2.

39.

Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: a retrospective analysis.

Bar J, Ng D, Moretto P, Goss GD, Sun A, Macrae R, Laurie SA, Leighl N, Nicholas G.

Clin Lung Cancer. 2013 Mar;14(2):200-4. doi: 10.1016/j.cllc.2012.05.008. Epub 2012 Aug 4.

PMID:
22868221
40.

β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol.

Vardeny O, Nicholas G, Andrei A, Buhr KA, Hermanson MP, Moran JJ, Detry MA, Stein JH.

Am J Hypertens. 2012 Aug;25(8):920-6. doi: 10.1038/ajh.2012.54. Epub 2012 May 31.

41.

Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.

Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D.

J Thorac Oncol. 2012 Mar;7(3):579-86. doi: 10.1097/JTO.0b013e31823f459c.

42.

Implementation of a stroke self-management program: A randomized controlled pilot study of veterans with stroke.

Damush TM, Ofner S, Yu Z, Plue L, Nicholas G, Williams LS.

Transl Behav Med. 2011 Dec;1(4):561-72. doi: 10.1007/s13142-011-0070-y.

43.

A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.

Mason WP, Belanger K, Nicholas G, Vallières I, Mathieu D, Kavan P, Desjardins A, Omuro A, Reymond D.

J Neurooncol. 2012 Apr;107(2):343-9. doi: 10.1007/s11060-011-0747-6. Epub 2011 Nov 3.

PMID:
22048878
44.

Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.

Laurie SA, Gupta A, Chu Q, Lee CW, Morzycki W, Feld R, Foo AH, Seely J, Goffin JR, Laberge F, Murray N, Rao S, Nicholas G, Laskin J, Reiman T, Sauciuc D, Seymour L.

J Thorac Oncol. 2011 Nov;6(11):1950-4. doi: 10.1097/JTO.0b013e3182333df5.

45.

Feather barbs as a good source of mtDNA for bird species identification in forensic wildlife investigations.

Speller CF, Nicholas GP, Yang DY.

Investig Genet. 2011 Jul 28;2:16. doi: 10.1186/2041-2223-2-16.

46.

Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting.

García PS, Cabbabe A, Kambadur R, Nicholas G, Csete M.

Anesth Analg. 2010 Sep;111(3):707-9. doi: 10.1213/ANE.0b013e3181eac1c9. Epub 2010 Aug 4.

PMID:
20686014
47.

metahdep: meta-analysis of hierarchically dependent gene expression studies.

Stevens JR, Nicholas G.

Bioinformatics. 2009 Oct 1;25(19):2619-20. doi: 10.1093/bioinformatics/btp468. Epub 2009 Jul 30.

PMID:
19648140
48.

Amplification of the Cotton effect of a single chromophore through liposomal ordering-stereochemical assignment of plakinic acids I and J.

Dalisay DS, Quach T, Nicholas GN, Molinski TF.

Angew Chem Int Ed Engl. 2009;48(24):4367-71. doi: 10.1002/anie.200900888.

49.

Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer.

Froeschl S, Nicholas G, Gallant V, Laurie SA.

J Thorac Oncol. 2008 Feb;3(2):163-9. doi: 10.1097/JTO.0b013e318160c0cb.

50.

Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP) study: design and practical implications of an intervention for comorbid pain and depression.

Kroenke K, Bair M, Damush T, Hoke S, Nicholas G, Kempf C, Huffman M, Wu J, Sutherland J.

Gen Hosp Psychiatry. 2007 Nov-Dec;29(6):506-17.

PMID:
18022044

Supplemental Content

Loading ...
Support Center